XETRA - Delayed Quote • EUR
Evotec SE (EVT.DE)
At close: April 26 at 5:35 PM GMT+2
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
820,802.00
751,448.00
618,034.00
500,924.00
Cost of Revenue
600,962.00
577,383.00
466,491.00
375,181.00
Gross Profit
219,840.00
174,065.00
151,543.00
125,743.00
Operating Expense
212,983.00
153,215.00
109,864.00
73,943.00
Operating Income
6,857.00
20,850.00
41,679.00
51,800.00
Net Non Operating Interest Income Expense
-117.00
-4,814.00
-6,982.00
-7,126.00
Other Income Expense
-80,832.00
-169,993.00
202,283.00
-18,834.00
Pretax Income
-74,092.00
-153,957.00
236,980.00
25,840.00
Tax Provision
20,892.00
21,698.00
21,470.00
19,562.00
Net Income Common Stockholders
-94,983.00
-175,655.00
215,510.00
6,278.00
Diluted NI Available to Com Stockholders
-94,983.00
-175,655.00
215,510.00
6,278.00
Basic EPS
-0.53
-0.99
1.30
0.04
Diluted EPS
-0.53
-0.99
1.30
0.04
Basic Average Shares
176,829.94
176,674.34
166,405.93
153,752.24
Diluted Average Shares
176,829.94
176,674.34
166,405.93
153,752.24
Total Operating Income as Reported
1,726.00
20,850.00
40,996.00
48,556.00
Total Expenses
813,945.00
730,598.00
576,355.00
449,124.00
Net Income from Continuing & Discontinued Operation
-94,983.00
-175,655.00
215,510.00
6,278.00
Normalized Income
-58,569.00
-45,348.30
16,429.61
12,334.40
Interest Income
10,719.00
8,336.00
2,272.00
1,339.00
Interest Expense
10,836.00
13,150.00
9,254.00
8,465.00
Net Interest Income
-117.00
-4,814.00
-6,982.00
-7,126.00
EBIT
-63,256.00
-140,807.00
246,234.00
34,305.00
EBITDA
-63,256.00
-59,148.00
313,842.00
90,363.00
Reconciled Cost of Revenue
600,962.00
577,383.00
466,491.00
375,181.00
Reconciled Depreciation
--
81,659.00
67,608.00
56,058.00
Net Income from Continuing Operation Net Minority Interest
-94,983.00
-175,655.00
215,510.00
6,278.00
Total Unusual Items Excluding Goodwill
-42,840.00
-153,302.00
218,914.00
-8,652.00
Total Unusual Items
-42,840.00
-153,302.00
218,914.00
-8,652.00
Normalized EBITDA
-20,416.00
94,154.00
94,928.00
99,015.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-6,426.00
-22,995.30
19,833.61
-2,595.60
12/31/2020 - 11/12/1999
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
AQST Aquestive Therapeutics, Inc.
4.0700
+3.56%
MRK.DE Merck KGaA
151.75
+1.10%
SBX.DE SynBiotic SE
9.86
+8.83%
SDZ.SW Sandoz Group AG
30.00
-2.31%
SBX.MU SynBiotic SE
9.56
+4.60%
ITCI Intra-Cellular Therapies, Inc.
73.26
+1.57%
SBFM Sunshine Biopharma, Inc.
0.9500
+17.66%
IP4.F InnoCan Pharma Corporation
0.1900
+2.98%
DMP.DE Dermapharm Holding SE
31.30
+0.81%
NBIX Neurocrine Biosciences, Inc.
135.99
-1.28%